Amethyst Piatra Neamt has officially opened its doors! Schedule an appointment
Amethyst Piatra Neamt has officially opened its doors! Schedule an appointment
Clinica RTC Radiology Therapeutic Center SRL este autorizată pentru desfăşurarea studiilor clinice cu beneficiu terapeutic pentru specialităţile de Oncologie Medicală şi Radioterapie conform autorizaţiei 814/2018.
1. MK-6482-022
A Multicenter, Double-Blind, Randomized Phase III Trial to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Carcinoma (ccRCC) Post Nephrectomy (6482-022).
2. MK 7339 – 012
A phase 3 study of Pembrolizumab (MK-3475) in combination with concurrent chemoradiotherapy followed by Pembrolizumab with or without olaparib vs concurrent chemoradiotherapy followed by Durvalumab in participants with unresectable stage III non-small cell lung cancer, locally advanced (NSCLC).
3. I3Y-MC-JPEG
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Abemaciclib in Combination with Abiraterone Plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer.
4. J2J-MC-JZLH
A randomized, open-label, phase III trial of Imlunestrant vs standard adjuvant endocrine therapy in patients who have received 2 to 5 years of prior adjuvant endocrine therapy for ER+, HER2- early breast cancer at high risk of recurrence.
5. AbbVie -M18-868
Phase III, Open-Label, Randomized Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with EGFR Wild-Type and c-Met Overexpression in Locally Advanced Non-Small Cell Non-Squamous Lung Cancer / previously metastatic.
6. R3767-ONC-2011
A Phase 3 Study of Fianlimab (REGN3767, Anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic
Melanoma.
7. Sanofi – EFC15858
Randomized, Open-Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non-Squamous Non-Squamous Lung Cancer Patients with CEACAM5-Positive Tumors.
8. ATLAS – 56021927PCR3003
A randomized, double-blind, placebo-controlled phase 3 study of JNJ-56021927 in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiotherapy.
1. MK-3475-671
A randomized, double-blind, phase III trial evaluating dual platinum-based chemotherapy +/- pembrolizumab (MK-3475) as neoadjuvant/adjuvant therapy in subjects diagnosed with non-small cell lung cancer (NSCLC, non- small cell lung cancer) operable in stage IIB or IIIA (KEYNOTE-671).
2. I3Y-MC-JPCF
Randomized Phase III Study of Abemaciclib in Combination with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy in Patients with High-Risk, Nodal, Hormone Receptor-High (HR+), Epidermal Growth Factor Early Breast Neoplasm receptor 2 negative (HER-2 negative) – monarchE: I3Y-MC-JPCF.
3. I3Y-MC-JPCM
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Abiraterone Acetate in Combination with Prednisone, Administered with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer.
4. ZEST – 213831
A randomized, double-blind, phase 3 study comparing the efficacy and safety of Niraparib to placebo in participants with HER 2-negative BRCA mutated or triple-negative breast cancer with molecular disease based on the presence of circulating tumor DNA after definitive therapy (ZEST ).
5. GlaxoSmithKline – 205801
Phase II study to study novel treatment regimens compared with standard treatment in non-small cell lung cancer.
6. GlaxoSmithKline – 209229
Randomized, Double-Blind, Adaptive Design Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of Patients with Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma, PD-L1 positive.
7. GlaxoSmithKline – 205801
Phase II study to study novel treatment regimens compared with standard treatment in non-small cell lung cancer.
8. GlaxoSmithKline – 209227
A randomized, double-blind, adaptive, phase II/III study of GSK3359609 in combination with Pembrolizumab and 5FU-Platinum chemotherapy versus placebo in combination with Pembrolizumab plus 5FU-Platinum chemotherapy for the first-line treatment of recurrent/metastatic squamous cell carcinoma of head and neck.
Dr. Ciubotaru Elena – primary medical oncology doctor
Amethyst Clinic Bucharest
Contact person: Raducanu (Mitca) Iuliana-Andreea
Phone: 021.9368
Address: no 42, Drumul Odăii, Otopeni, Ilfov County
Phone: 021.9368
Address: no 486G, Răzoare Street, Florești, Cluj County
Phone: 021.9368
Address: no 12, Bela Bartok Street, Dumbrăvița, Timiș County
Phone: 021.9368
Address: no 10, Louis Pasteur Street, Alba-Iulia, Alba County
Phone: 021.9368
Address: no 31H, Ion Ionescu de la Brad, Piatra Neamț, Neamț County
Phone: 021.9368
Address: no 9, Dunării Street, Satu Mare, Satu Mare County
